Cite
Patel MA, Kim JE, Theodros D, et al. Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma. J Immunother Cancer. 2016;4:28doi: 10.1186/s40425-016-0132-2.
Patel, M. A., Kim, J. E., Theodros, D., Tam, A., Velarde, E., Kochel, C. M., Francica, B., Nirschl, T. R., Ghasemzadeh, A., Mathios, D., Harris-Bookman, S., Jackson, C. C., Jackson, C., Ye, X., Tran, P. T., Tyler, B., Coric, V., Selby, M., Brem, H., Drake, C. G., Pardoll, D. M., & Lim, M. (2016). Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma. Journal for immunotherapy of cancer, 428. https://doi.org/10.1186/s40425-016-0132-2
Patel, Mira A, et al. "Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma." Journal for immunotherapy of cancer vol. 4 (2016): 28. doi: https://doi.org/10.1186/s40425-016-0132-2
Patel MA, Kim JE, Theodros D, Tam A, Velarde E, Kochel CM, Francica B, Nirschl TR, Ghasemzadeh A, Mathios D, Harris-Bookman S, Jackson CC, Jackson C, Ye X, Tran PT, Tyler B, Coric V, Selby M, Brem H, Drake CG, Pardoll DM, Lim M. Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma. J Immunother Cancer. 2016 May 17;4:28. doi: 10.1186/s40425-016-0132-2. eCollection 2016. PMID: 27190629; PMCID: PMC4869343.
Copy
Download .nbib